Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share. Aerie Pharmaceuticals develops treatments for patients with glaucoma and other eye diseases. Aerie's two main products are intraocular pressure-lowering drugs and treatments for patients with glaucoma or ocular hypertension.